Denali Therapeutics, an early-stage biotech developing novel therapies for neurodegenerative diseases, raised $250 million by offering 13.9 million shares at $18, within the range of $17 to $19. At pricing, the company commands a fully diluted market value of $1.7 billion. Denali Therapeutics plans to list on the Nasdaq under the symbol DNLI. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as lead managers on the deal.
